Author Archives: Bruno Quinney

Nasal spray
#Asthma #EMA

Tezpire recommended in EU to treat chronic rhinosinusitis

AstraZeneca and Amgen’s drug Tezspire (tezepelumab) has been recommended for approval in the European Union for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP).   The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on… Read More

#News

Peanuts
#Allergy #Biopharmaceutical

Prota awarded for research on peanut oral immunotherapy

Biopharmaceutical company Prota Therapeutics has announced its research, in partnership with Murdoch Children’s Research Institute (MCRI), has been awarded a prize at the European Academy of Allergy and Clinical Immunology (EAACI) for outstanding oral abstract presentation.  The presentation reported three-year post-treatment findings from the Phase IIb PPOIT-003… Read More

#News

Eye
#Diabetic macular oedema

Positive results in Phase II trial of migaldendranib for DMO and nAMD

Ashvattha Therapeutics has announced positive results in the Phase II trial of migaldendranib (MGB), a targeted nanomedicine for the treatment of diabetic macular oedema (DMO) and neovascular age-related macular degeneration (nAMD).  The findings showed the annualised rate of IVT injections in all study eyes decreased from 8.4… Read More

#News

Antibodies
#Bispecific Antibodies #Financing

Dualitas Therapeutics to develop next-gen specific antibodies

Biotechnology company Dualitas Therapeutics has launched from stealth with a $65 million (£48 million) Series A financing round to develop next-generation bispecific antibodies (BsAbs).  The company’s financing is co-led by Versant Ventures and Qiming Venture Partners USA, with participation from founding investor SV Health Investors and new… Read More

#News

Artificial intelligence
#AI #Data #Drug discovery #Merck

Merck and Siemens extend partnership for AI projects 

US pharmaceutical giant Merck and technology company Siemens have signed a new Memorandum of Understanding (MoU), extending their strategic partnership to accelerate AI and data-driven drug discovery and development.  The MoU focuses on delivering integrated software solutions, systems and consumables that harness automation, data and AI to connect drug discovery,… Read More

#Business & Investment #News

#AI #Gene editing

Revvity and Profluent collaborate on gene-editing toolkit

Revvity has announced a collaboration with biotechnology company Profluent to accelerate the development of novel gene-editing therapies.  The collaboration will bring together a range of Profluent’s novel AI-engineered enzymes with Revvity’s established Pin-point base editing platform, creating a therapeutically relevant base editing toolkit.  The new Pin-point configuration will allow for increased… Read More

#Business & Investment #News

Cholesterol test
#Cholesterol #Japan

Nexletol receives regulatory approval in Japan

 Hypercholesterolaemia treatment Nexletol has received regulatory approval from the Japanese Ministry of Health, Labour and Welfare.  The announcement was made by US pharmaceutical company Esperion, whose partner Otsuka Pharmaceutical has developed and commercialised Nexletol. The product is a treatment for hypercholesterolaemia and familial hypercholesterolaemia. … Read More

#News

Deal making concept
#Biotech

Biotechnology companies reach agreement to advance vectorised antibodies

Biotechnology companies VectorY Therapeutics and Shape Therapeutics have reached an exclusive license agreement to develop vectorised antibodies for neurodegenerative diseases.  The agreement grants VectorY an exclusive option to evaluate Shape’s deep-brain penetrating adeno-associated virus (AAV) capsid, SHP-DB1, for vectorised antibody payloads against three therapeutic targets. Shape will grant access to its proprietary capsid… Read More

#Business & Investment #News

#CSL Behring

NICE recommends garadacimab for prevention of HAE attacks

The UK National Institute for Health and Care Excellence (NICE) has recommended Andembry (garadacimab) for the prevention of hereditary angioedema (HAE) attacks, biopharmaceutical company CSL Behring has announced.  The recommendation follows results from the Phase III VANGUARD trial, which found garadacimab significantly reduced the mean number of… Read More

#News

Asthma inhaler
#Celltrion

Omlyclo set to become commercially available in Europe

The drug Omlyclo, the first and only omalizumab biosimilar in Europe, will be commercially available in the European market, biopharmaceutical company Celltrion has announced.  Omlyclo, a drug used to treat chronic spontaneous urticaria (CSU), allergic asthma and chronic rhinosinusitis with nasal polyps, will be available in Norway… Read More

#News

Laboratory research
#FDA

LP-10 could become first FDA-approved OLP treatment

Promising results from a clinical trial of LP-10 suggest the drug could become the first FDA-approved therapy for symptomatic oral lichen planus (OLP). LP-10, a proprietary liposomal tacrolimus oral rinse, was evaluated in a Phase IIa multicentre, dose-ranging clinical trial. Twenty-seven patients completed a four-week treatment course with… Read More

#News

This week in Drug Discovery (15 – 19 September) 

News round-up for 15 – 19 September by Bruno Quinney, Content Team at DDW.  Stories from the drug discovery industry have continued to make headlines this week, with high-level investment from GSK in the US coming at a time when big pharma companies have halted investment in… Read More

#News

#DDW Highlights podcast

DDW Highlights: 19 September 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In this week’s news, AstraZeneca has halted its £200 million research investment in the UK. Read More

#Podcasts

Subcutaneous injection
#Clinical trial

First patient dosed in Phase I trial of antibody-drug conjugate TJ101

The first patient has been dosed in the Phase I clinical trial of the antibody-drug conjugate (ADC) TJ101, Phrontline Biopharma has announced. The Phase I study of TJ101, targeting EGFR/B7-H3, will evaluate its safety, tolerability, pharmacokinetics, and preliminary antitumour activity across multiple solid tumour types. The study design… Read More

#News

GBP pound sterling funding
#Enhanced Genomics #Investment

Enhanced Genomics receives new funding worth $19 million

Biotechnology company Enhanced Genomics has received new investment in its Series A programme, the company has announced.  Enhanced Genomics, known for pioneering 3D multi-omics to rapidly identify high-confidence, genetically-validated drug targets for common diseases, has received $19 million (£14 million) from BGF, Parkwalk and Meltwind. The funding will be used… Read More

#Business & Investment #News